Details of the Drug

General Information of Drug (ID: DMCXN80)

Drug Name
Tozorakimab
Indication
Disease Entry ICD 11 Status REF
Acute respiratory failure CB41.0 Phase 3 [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D0YFN1
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-33 (IL33) TT5MD4P IL33_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute respiratory failure
ICD Disease Classification CB41.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-33 (IL33) DTT IL33 1.19E-01 -0.03 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05624450) A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
3 ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691.